RE:Globe says Partheniou keeps Valens Group at "buy" ...I've said it before, and I'll say it again - this is not a company that issues "fluff" news releases just to pump the share price. We've all seen plenty of that, especially anyone who has previoulsy been invested in THC Bioscam. I've been invested in Valens since August 2018 and in my experience this company delivers on its stated goals. That being the case, we have a lot of important news coming in the next week, followed by release of Q2 results around July 16. I managed to come up with a couple thousand bucks to buy at $3.10 a couple of days ago...long and strong here. Go Valens!
mesa1 wrote: 2021-06-23 05:45 PT - In the News
The Globe and Mail reports in its Wednesday, June 23, edition that Stifel analyst Andrew Partheniou has come off research restriction on The Valens Company ($3.07) after it closed its $40-million (U.S.) acquisition of Green Roads (all figure Canadian unless otherwise stated). The Globe's David Leeder writes in the Eye On Equities column that accordingly, Mr. Partheniou boosted his share target to $5.75 from $3.75 with an unchanged "buy" recommendation. Analysts on average target the shares at $4.44. Mr. Partheniou says in a note: "We see a company that has fortified its operations with the entry into the U.S. CBD industry through a leading brand, the launch of its first flower products at aggressive prices and a $46-million equity financing that results in a proforma cash position of $70-million (excluding earnout). In short, VLNS has executed on what management has promised, proving its suitable comps are with Tier 1 LPs, in our view." The Globe reported on Oct. 17 that Desjardins Securities analyst John Chu was sticking with his "buy" ranking. The shares were then worth $1.73. The Globe reported on Jan. 22 that Mr. Chu still rated the shares "buy," which were then worth $2.28.